119th Congress · introduced in the Senate · Jun 12, 2025
RAPID Reserve Act
Official title from Congress.gov
Latest action (Jun 12, 2025): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
29 citations; showing the 25 most recently posted.
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$390,000
Spent on own lobbying
…al efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Manufacturing
$390,000
Spent on own lobbying
…al efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 18, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
…t on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$370,000
Spent on own lobbying
…al efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Manufacturing
$370,000
Spent on own lobbying
…al efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 18, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…ted to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
…t on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR ACCESSIBLE MEDICINES · lobbying firm or registrant: ASSOCIATION FOR ACCESSIBLE MEDICINES
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$840,000
Spent on own lobbying
…H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469: BIOSECURE…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$400,000
Spent on own lobbying
…al efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Manufacturing
$400,000
Spent on own lobbying
…al efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 15, 2026 · issue area: Health Issues
$210,000
Spent on own lobbying
…t on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN HOSPITAL ASSOCIATION · lobbying firm or registrant: AMERICAN HOSPITAL ASSOCIATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$6,570,000
Spent on own lobbying
…/ H.R. 4191, The Mapping America's Pharmaceutical Supply (MAPS) Act, all provisions; H.R. 5283 / S. 2759, Healthcare Workforce Resilience Act, all provisions; S. 2062, The Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, all provisions; H.R. 5256, 340B Access Act, all provisions; S. 1929, SEPSIS…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
…t on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$410,000
Spent on own lobbying
…utical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Manufacturing
$410,000
Spent on own lobbying
…utical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: TIBER CREEK GROUP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 17, 2026 · issue area: Budget/Appropriations
$90,000
Paid to lobbying firm
…related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$420,000
Spent on own lobbying
…utical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Manufacturing
$420,000
Spent on own lobbying
…utical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR ACCESSIBLE MEDICINES · lobbying firm or registrant: ASSOCIATION FOR ACCESSIBLE MEDICINES
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Pharmacy
$640,000
Spent on own lobbying
…ial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. Es…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN HOSPITAL ASSOCIATION · lobbying firm or registrant: AMERICAN HOSPITAL ASSOCIATION
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$5,720,000
Spent on own lobbying
…rization Act, all provisions; S. 1929, SEPSIS Act, all provisions; H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025, all provisions; S. 2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID) Reserve Act, all provisions; S. 921, Tyler's Law, all provisions; H.R. 3482, Veterans Commun…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR CLINICAL ONCOLOGY · lobbying firm or registrant: ASSOCIATION FOR CLINICAL ONCOLOGY
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$110,000
Spent on own lobbying
…t on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN HOSPITAL ASSOCIATION · lobbying firm or registrant: AMERICAN HOSPITAL ASSOCIATION
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$6,150,000
Spent on own lobbying
…91, The Mapping America's Pharmaceutical Supply (MAPS) Act, all provisions; S. 229 / H.R. 3789, Drug Price Transparency for Consumer (DTC) Act, all provisions; S. 2062, Rapid Reserve Act, all provisions; Draft Bill, Medical Debt Prevention and Relief Act of 2025, all provisions; S. 1929, SEPSIS Act, all provisions; H.R. 2483,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHLOW CORPORATION · lobbying firm or registrant: PHLOW CORPORATION
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$380,000
Spent on own lobbying
…utical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug produ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing